Klas Gosta Wiman
Corporate Officer/Principal at Karolinska Institutet
Klas Gosta Wiman active positions
| Companies | Position | Start | End |
|---|---|---|---|
| Karolinska Institutet | Corporate Officer/Principal | 14/05/2009 | - |
Career history of Klas Gosta Wiman
Former positions of Klas Gosta Wiman
| Companies | Position | Start | End |
|---|---|---|---|
| APREA THERAPEUTICS, INC. | Founder | 31/12/2001 | - |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Director/Board Member | 31/12/2002 | - |
| Founder | 31/12/2002 | - |
Statistics
International
| Sweden | 3 |
| United States | 2 |
Operational
| Founder | 2 |
| Director/Board Member | 1 |
| Corporate Officer/Principal | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| APREA THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
- Stock Market
- Insiders
- Klas Gosta Wiman
- Experience